Background Guselkumab is an interleukin (IL)-23 pathway blocker with proven efficacy in patients with moderate-to-severe plaque psoriasis. Early intervention with guselkumab may result in changes to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results